Skip to main content
. 2021 Jun 16;11(6):113. doi: 10.1038/s41408-021-00506-3

Table 2.

Site of CNS relapse by CNS prophylaxis.

Site of CNS relapse
CNS prophylaxis regimen Leptomeninges Parenchyma Both
IT 5 (42%) 3 (25%) 4 (33%)
HD-MTX 1 (50%) 1 (50%)
No prophylaxis 5 (23%) 13 (57%) 4 (18%)

CNS central nervous system, IT intrathecal, MTX methotrexate, HD high-dose.